Nanotechnologies to use zoledronic acid as a potent antitumoral agent

G. Salzano, M. Marra, C. Leonetti, M. Porru, S. Zappavigna, A. Abbruzzese, M. I. La Rotonda, M. Caraglia, G. De Rosa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Zoledronic acid, a new highly potent third generation aminobisphosphonate, is the drug currently used to prevent bone resorption in patients with bone metastases. Moreover, ZOL is a potent inducer of apoptosis in several cancer cell types, suggesting a direct anti-cancer activity that may affect a broad range of tumors. However, the rapid elimination from plasma, along with the rapid uptake and accumulation within bone, hampers the direct anti-cancer activity of ZOL in vivo. On the other hand, long circulating nanocarriers offer the opportunity to change the pharmacokinetics of encapsulated drugs, targeting tissues with an increased permeability of the vessels (e.g. tumors). In this study, we proposed two different strategies in order to avoid ZOL accumulation in bone and address the drug toward tumors. In particular, we designed and developed long circulating liposomes and self-assembly PEGylated nanoparticles for the delivery of ZOL into solid tumors.

Original languageEnglish
Pages (from-to)283-284
Number of pages2
JournalJournal of Drug Delivery Science and Technology
Volume21
Issue number3
Publication statusPublished - May 2011

Fingerprint

zoledronic acid
Nanotechnology
Neoplasms
Bone and Bones
Drug Delivery Systems
Bone Resorption
Liposomes
Pharmaceutical Preparations
Nanoparticles
Permeability

Keywords

  • Self-assembly nanoparticles
  • Stealth liposomes
  • Zoledronic acid

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Salzano, G., Marra, M., Leonetti, C., Porru, M., Zappavigna, S., Abbruzzese, A., ... De Rosa, G. (2011). Nanotechnologies to use zoledronic acid as a potent antitumoral agent. Journal of Drug Delivery Science and Technology, 21(3), 283-284.

Nanotechnologies to use zoledronic acid as a potent antitumoral agent. / Salzano, G.; Marra, M.; Leonetti, C.; Porru, M.; Zappavigna, S.; Abbruzzese, A.; La Rotonda, M. I.; Caraglia, M.; De Rosa, G.

In: Journal of Drug Delivery Science and Technology, Vol. 21, No. 3, 05.2011, p. 283-284.

Research output: Contribution to journalArticle

Salzano, G, Marra, M, Leonetti, C, Porru, M, Zappavigna, S, Abbruzzese, A, La Rotonda, MI, Caraglia, M & De Rosa, G 2011, 'Nanotechnologies to use zoledronic acid as a potent antitumoral agent', Journal of Drug Delivery Science and Technology, vol. 21, no. 3, pp. 283-284.
Salzano G, Marra M, Leonetti C, Porru M, Zappavigna S, Abbruzzese A et al. Nanotechnologies to use zoledronic acid as a potent antitumoral agent. Journal of Drug Delivery Science and Technology. 2011 May;21(3):283-284.
Salzano, G. ; Marra, M. ; Leonetti, C. ; Porru, M. ; Zappavigna, S. ; Abbruzzese, A. ; La Rotonda, M. I. ; Caraglia, M. ; De Rosa, G. / Nanotechnologies to use zoledronic acid as a potent antitumoral agent. In: Journal of Drug Delivery Science and Technology. 2011 ; Vol. 21, No. 3. pp. 283-284.
@article{2705f48e3aad452fbf4c5f2b88084697,
title = "Nanotechnologies to use zoledronic acid as a potent antitumoral agent",
abstract = "Zoledronic acid, a new highly potent third generation aminobisphosphonate, is the drug currently used to prevent bone resorption in patients with bone metastases. Moreover, ZOL is a potent inducer of apoptosis in several cancer cell types, suggesting a direct anti-cancer activity that may affect a broad range of tumors. However, the rapid elimination from plasma, along with the rapid uptake and accumulation within bone, hampers the direct anti-cancer activity of ZOL in vivo. On the other hand, long circulating nanocarriers offer the opportunity to change the pharmacokinetics of encapsulated drugs, targeting tissues with an increased permeability of the vessels (e.g. tumors). In this study, we proposed two different strategies in order to avoid ZOL accumulation in bone and address the drug toward tumors. In particular, we designed and developed long circulating liposomes and self-assembly PEGylated nanoparticles for the delivery of ZOL into solid tumors.",
keywords = "Self-assembly nanoparticles, Stealth liposomes, Zoledronic acid",
author = "G. Salzano and M. Marra and C. Leonetti and M. Porru and S. Zappavigna and A. Abbruzzese and {La Rotonda}, {M. I.} and M. Caraglia and {De Rosa}, G.",
year = "2011",
month = "5",
language = "English",
volume = "21",
pages = "283--284",
journal = "Journal of Drug Delivery Science and Technology",
issn = "1773-2247",
publisher = "Editions de Sante",
number = "3",

}

TY - JOUR

T1 - Nanotechnologies to use zoledronic acid as a potent antitumoral agent

AU - Salzano, G.

AU - Marra, M.

AU - Leonetti, C.

AU - Porru, M.

AU - Zappavigna, S.

AU - Abbruzzese, A.

AU - La Rotonda, M. I.

AU - Caraglia, M.

AU - De Rosa, G.

PY - 2011/5

Y1 - 2011/5

N2 - Zoledronic acid, a new highly potent third generation aminobisphosphonate, is the drug currently used to prevent bone resorption in patients with bone metastases. Moreover, ZOL is a potent inducer of apoptosis in several cancer cell types, suggesting a direct anti-cancer activity that may affect a broad range of tumors. However, the rapid elimination from plasma, along with the rapid uptake and accumulation within bone, hampers the direct anti-cancer activity of ZOL in vivo. On the other hand, long circulating nanocarriers offer the opportunity to change the pharmacokinetics of encapsulated drugs, targeting tissues with an increased permeability of the vessels (e.g. tumors). In this study, we proposed two different strategies in order to avoid ZOL accumulation in bone and address the drug toward tumors. In particular, we designed and developed long circulating liposomes and self-assembly PEGylated nanoparticles for the delivery of ZOL into solid tumors.

AB - Zoledronic acid, a new highly potent third generation aminobisphosphonate, is the drug currently used to prevent bone resorption in patients with bone metastases. Moreover, ZOL is a potent inducer of apoptosis in several cancer cell types, suggesting a direct anti-cancer activity that may affect a broad range of tumors. However, the rapid elimination from plasma, along with the rapid uptake and accumulation within bone, hampers the direct anti-cancer activity of ZOL in vivo. On the other hand, long circulating nanocarriers offer the opportunity to change the pharmacokinetics of encapsulated drugs, targeting tissues with an increased permeability of the vessels (e.g. tumors). In this study, we proposed two different strategies in order to avoid ZOL accumulation in bone and address the drug toward tumors. In particular, we designed and developed long circulating liposomes and self-assembly PEGylated nanoparticles for the delivery of ZOL into solid tumors.

KW - Self-assembly nanoparticles

KW - Stealth liposomes

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=79959670578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959670578&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79959670578

VL - 21

SP - 283

EP - 284

JO - Journal of Drug Delivery Science and Technology

JF - Journal of Drug Delivery Science and Technology

SN - 1773-2247

IS - 3

ER -